AVTX
Avalo Therapeutics, Inc.
Biotechnology
Market Cap$404M
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AVTX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.83B
5Y Perf.+11.7%
AVTX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AVTX | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $404M | $5.83B |
| Revenue (TTM) | $-209K | $0.00 |
| Net Income (TTM) | $-78M | $-464M |
| Operating Margin | -1236.0% | — |
| Total Debt | $0.00 | $98K |
| Cash & Equiv. | $16M | $714M |
AVTX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AVTX
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Avalo Therapeutics,… (AVTX) | 100 | 0.2 | -99.8% |
| Immunovant, Inc. (IMVT) | 100 | 111.7 | +11.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AVTX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMVT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Avalo Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
AVTX
Avalo Therapeutics, Inc.
The Income Pick
AVTX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.21
- Lower volatility, beta 1.21, current ratio 8.14x
- Beta 1.21, current ratio 8.14x
Best for: income & stability and sleep-well-at-night
IMVT
Immunovant, Inc.
The Growth Play
IMVT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth -45.2%
- 188.1% 10Y total return vs AVTX's -99.8%
- -21.3% revenue growth vs AVTX's -86.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs AVTX's -86.6% |
| Quality / Margins | IMVT | 3.2% margin vs AVTX's -1.3K% |
| Stability / Safety | AVTX | Beta 1.21 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | AVTX | +356.3% vs IMVT's +107.2% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs AVTX's -61.8% |
AVTX vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
AVTX vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGAVTX
AVTXAvalo Therapeutics, I…
0leads
IMVTImmunovant, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs AVTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IMVT and AVTX operate at a comparable scale, with $0 and -$209,000 in trailing revenue.
| Metric | AVTXAvalo Therapeutic… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | -$209,000 | $0 |
| EBITDAEarnings before interest/tax | -$72M | -$487M |
| Net IncomeAfter-tax profit | -$78M | -$464M |
| Free Cash FlowCash after capex | -$51M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | -1236.0% | — |
| Net MarginNet income ÷ Revenue | -1326.4% | — |
| FCF MarginFCF ÷ Revenue | -872.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -104.6% | +19.7% |
IMVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — AVTX and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | AVTXAvalo Therapeutic… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $404M | $5.8B |
| Enterprise ValueMkt cap + debt − cash | $388M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -3.73x | -10.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 6843.44x | — |
| Price / BookPrice ÷ Book value/share | 3.52x | 6.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — AVTX and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-78 for AVTX. On the Piotroski fundamental quality scale (0–9), IMVT scores 2/9 vs AVTX's 1/9, reflecting mixed financial health.
| Metric | AVTXAvalo Therapeutic… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -77.9% | -47.1% |
| ROA (TTM)Return on assets | -61.8% | -44.1% |
| ROICReturn on invested capital | -165.1% | — |
| ROCEReturn on capital employed | -59.0% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$16M | -$714M |
| Cash & Equiv.Liquid assets | $16M | $714M |
| Total DebtShort + long-term debt | $0 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
IMVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $17,386 today (with dividends reinvested), compared to $27 for AVTX. Over the past 12 months, AVTX leads with a +356.3% total return vs IMVT's +107.2%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.1% vs AVTX's -67.5% — a key indicator of consistent wealth creation.
| Metric | AVTXAvalo Therapeutic… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +28.1% | +10.7% |
| 1-Year ReturnPast 12 months | +356.3% | +107.2% |
| 3-Year ReturnCumulative with dividends | -96.6% | +48.4% |
| 5-Year ReturnCumulative with dividends | -99.7% | +73.9% |
| 10-Year ReturnCumulative with dividends | -99.8% | +188.1% |
| CAGR (3Y)Annualised 3-year return | -67.5% | +14.1% |
IMVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AVTX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
AVTX is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 95.3% from its 52-week high vs AVTX's 92.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AVTXAvalo Therapeutic… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 1.37x |
| 52-Week HighHighest price in past year | $23.71 | $30.09 |
| 52-Week LowLowest price in past year | $3.39 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +92.0% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 60.8 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 1.4M |
Evenly matched — AVTX and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AVTX as "Buy" and IMVT as "Buy". Consensus price targets imply 109.4% upside for AVTX (target: $46) vs 58.7% for IMVT (target: $46).
| Metric | AVTXAvalo Therapeutic… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $45.67 | $45.50 |
| # AnalystsCovering analysts | 5 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallImmunovant, Inc. (IMVT)Leads 3 of 6 categories
Loading custom metrics...
AVTX vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AVTX or IMVT a better buy right now?
Analysts rate Avalo Therapeutics, Inc.
(AVTX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AVTX or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +73. 9%, compared to -99. 7% for Avalo Therapeutics, Inc. (AVTX). Over 10 years, the gap is even starker: IMVT returned +188. 1% versus AVTX's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AVTX or IMVT?
By beta (market sensitivity over 5 years), Avalo Therapeutics, Inc.
(AVTX) is the lower-risk stock at 1. 21β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 13% more volatile than AVTX relative to the S&P 500.
04Which is growing faster — AVTX or IMVT?
On earnings-per-share growth, the picture is similar: Immunovant, Inc.
grew EPS -45. 2% year-over-year, compared to -79. 1% for Avalo Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AVTX or IMVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -1326. 4% for Avalo Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -1236. 0% for AVTX. At the gross margin level — before operating expenses — AVTX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AVTX or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AVTX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+188. 1% 10Y return). Both have compounded well over 10 years (IMVT: +188. 1%, AVTX: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AVTX and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.